Literature DB >> 28718903

Affairs of the Heart: Innovation in Cardiovascular Research and Development.

P Honig1, A Terzic2.   

Abstract

Cardiovascular disease represents the single largest contributor to morbidity and mortality, yet the flow of therapeutic innovation is lagging. Globally, academia, industry, and regulatory agencies must work together to address this gap, and ensure new disruptive therapeutic modalities to address growing needs of patients and society.
© 2017 ASCPT.

Entities:  

Mesh:

Year:  2017        PMID: 28718903     DOI: 10.1002/cpt.737

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  6 in total

1.  Process Improvement for Maximized Therapeutic Innovation Outcome.

Authors:  Scott A Waldman; Andre Terzic
Journal:  Clin Pharmacol Ther       Date:  2018-01       Impact factor: 6.875

2.  Health Care Evolves From Reactive to Proactive.

Authors:  Scott A Waldman; Andre Terzic
Journal:  Clin Pharmacol Ther       Date:  2019-01       Impact factor: 6.875

Review 3.  The noncoding-RNA landscape in cardiovascular health and disease.

Authors:  Vittoria Di Mauro; Maria Barandalla-Sobrados; Daniele Catalucci
Journal:  Noncoding RNA Res       Date:  2018-02-09

4.  Overcoming the Declining Trends in Innovation and Investment in Cardiovascular Therapeutics: Beyond EROOM's Law.

Authors:  Gail A Van Norman
Journal:  JACC Basic Transl Sci       Date:  2017-10-30

Review 5.  Mass Customized Outlook for Regenerative Heart Failure Care.

Authors:  Satsuki Yamada; Jozef Bartunek; Atta Behfar; Andre Terzic
Journal:  Int J Mol Sci       Date:  2021-10-22       Impact factor: 5.923

6.  Screening for regenerative therapy responders in heart failure.

Authors:  Satsuki Yamada; Ryounghoon Jeon; Armin Garmany; Atta Behfar; Andre Terzic
Journal:  Biomark Med       Date:  2021-06-25       Impact factor: 2.851

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.